News & Announcements
-
Imaging Biometrics Touts Position Paper for Monitoring High-Grade Glioma Treatment Response Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated
Milwaukee – 7 March 2022: Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
-
MD ANDERSON ADOPTS IB CLINIC FOR BRAIN TUMOR ANALYSIS
Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual…
-
PUBLISHED NEUROSURGERY CASE REPORT UNDERSCORES CLINICAL VALUE OF IB SOFTWARE AFFILIATED HOSPITAL PURCHASES IB CLINIC FOR AUTOMATED ANALYSIS
Milwaukee – 1 October 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors.
-
IQ-AI LIMITED AWARDED EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced it has been awarded a European Patent for “Multiparameter Perfusion Imaging…
-
IQ-AI LIMITED SOFTWARE CHOSEN FOR QUANTITATIVE ACCURACY AND AUTOMATION
Sales of Renewal Licenses for Established Clients and a New Installation of IB Clinic at the Eastern Alabama Medical Center.